Key result
The new formulation of rebamipide 150 mg twice daily was noninferior to rebamipide 100 mg thrice daily in improving gastric erosions, with an improvement rate difference of -4.01% (95% CI, -13.09% to 5.06%).
Why the study?
Does AD-203 (rebamipide 150 mg) improve erosion improvement rate in patients with erosive gastritis compared to rebamipide 100 mg?
RCT (n=475)
Double-blind
1:1
Yes
Does AD-203 (rebamipide 150 mg) improve erosion improvement rate in patients with erosive gastritis compared to rebamipide 100 mg?
Mean Difference: -4.01 (95% CI -13.09–5.06)
Absolute Event Rate: 39.7% vs 43.8%
p-value: p=0.387
The new formulation AD-203 (rebamipide 150 mg) demonstrates similar efficacy and safety to standard rebamipide 100 mg in treating erosive gastritis.
AD-203 twice daily is noninferior for erosive gastritis; extends dosing-convenience evidence for rebamipide in RCTs.
Background/Aims: (rebamipide 100 mg) and its new formulation, AD-203 (rebamipide 150 mg), in treating erosive gastritis. Methods: , n=215). The posttreatment assessments included the primary (erosion improvement rate) and secondary endpoints (erosion and edema cure rates; improvement rates of redness, hemorrhage, and gastrointestinal symptoms). Drug-related adverse events were evaluated. Results: -treated patients reported adverse events but no serious adverse drug reactions; both groups presented similar adverse event rates. Conclusions: ) thrice daily. Both formulations showed a similar efficacy in treating erosive gastritis.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2021) conducted an RCT in Erosive gastritis (n=475). AD-203 (rebamipide new formulation) vs. Mucosta (rebamipide 100 mg) thrice daily was evaluated on Erosion improvement rate at 2 weeks (Difference -4.01%, 95% CI -13.09% to 5.06%, p=0.387). The new formulation of rebamipide 150 mg twice daily was noninferior to rebamipide 100 mg thrice daily in improving gastric erosions, with an improvement rate difference of -4.01% (95% CI, -13.09% to 5.06%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: